Data Insights
By Company Name
No filters selected
By Disease Name
No filters selected
By Drug Name
No filters selected
By Themes
No filters selected
Showing 2 results out of 2
Data Insights
Risk adjusted net present value: What is the current valuation of CRISPR Therapeutics's CTX-130?
CTX-130 is a gene-modified cell therapy commercialized by CRISPR Therapeutics, with a leading Phase I program in T-Cell Lymphomas. According...
Data Insights
Risk adjusted net present value: What is the current valuation of CRISPR Therapeutics's CTX-130?
CTX-130 is a gene-modified cell therapy commercialized by CRISPR Therapeutics, with a leading Phase I program in T-Cell Lymphomas. According...